<DOC>
	<DOCNO>NCT02226705</DOCNO>
	<brief_summary>Radical endoscopic transnasal surgery associate medical treatment liposomal amphotericine B may increase local control Rhino-Sinusal Mucormycosis survival rate . The objective study evaluate local control rate survival rate 3 month radical endoscopic transnasal surgery extend towards skull base association antifungal therapy early surgical reevaluation extent disease .</brief_summary>
	<brief_title>Endoscopic Surgical Treatment Rhino-Sinusal Mucormycosis</brief_title>
	<detailed_description>Introduction : Treatment Rhino-Sinusal Mucormycosis remain challenge severity disease high mortality rate . Mainly involve diabetic immunodeficient patient , first clinical presentation common infection sinus extend towards deep space face , orbit , skull base brain . The mortality rate range 20 50 % , 80 % case cerebral extension . Transnasal Endoscopic Surgery extend Skull Base . Hypothesis : We hypothesize infected tissue devascularized antifungal therapy hardly reach area infect tissue . Radical endoscopic transnasal surgery associate medical treatment liposomal amphotericine B may increase local control disease survival rate . Clinical evaluation extent disease within first 7 day follow initial surgery may represent prognosis factor . Methods : First national mutlicentric multidisciplinary cohort Rhino-Sinusal Mucormycosis Radiological stag evaluation extent disease use CT scan , MRI PET Scan initial stage surgery Radical surgery and/or endoscopic transnasal surgery extend towards skull base associate liposomal amphotericine B medical treatment . At day 7 new radiological evaluation second surgical look adapt surgical resection infect tissue , perform biopsy search mycormycosis , biofilms dosage concentration liposomal amphotericin B inside tissue . New radiological surgical look case absence local control obtain second look . Study response rate endoscopic &amp; scan follow-up ( biopsy anatomopathological et mycological study ) 1 month , 3 month , 6 month &amp; one year . PET scan initially &amp; 3 month . Number subject include : Phase II type trial ( exclusion zero hypothesis survival rate &lt; 50 % ) , N= 23 patient Total length study 4 year Inclusion period time : 3 year Time participation per patient : 1 year Number center and/or participate department : 24 Mean number patient include per year per center : 0 3 patient</detailed_description>
	<mesh_term>Mucormycosis</mesh_term>
	<mesh_term>Zygomycosis</mesh_term>
	<criteria>Man woman , 18 year old , present mucormycosis sinus biopsy show large filament non little septae compatible mucoral positive culture mucoral sinus sample associate clinical head &amp; neack anomaly ( endoscopic ) &amp; scan compatible mucormycosis previous inclusion whatever patient incumbent pathology . Patient treat liposomal amphotericin B treat Signature informed consent : patient able express family close , patient unable consent Inclusion emergency clause possible ( CPP agreement ) patient incapacitate , close present surgery urgent Person affiliate Health Security System ( beneficiary ) Pregnancy , breastfeed Disseminated Mucormycosis ( involvment one site distant head neck ) Known hypersensitivity polyene Absence documentation mucormycosis ( histological , mycological ) Contraindication completion surgery provide protocol Patient subject guardianship tutelage measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rhinocerebral Mucormycosis</keyword>
	<keyword>Surgery</keyword>
	<keyword>Fungal Infection</keyword>
	<keyword>Survival</keyword>
</DOC>